The aim of this project is to develop a business plan to guide clinical development and commercialisation of SI053; a novel gel formulation for the treatment of the most common and aggressive type of brain cancer called glioblastoma.
Glioblastoma affects approximately 2-3 people in every 100,000 each year in Europe and has an extremely poor prognosis. 50% of patients die within a year and 90% die within three years. A combination of treatments are used to treat patients but are limited in their efficacy due to the physical location of the tumour and the aggressiveness of the condition.
Double Bond has developed SI053, a unique polymer matrix that contains temozolomide to locally treat brain tumours without harming healthy tissue. Temozolomide is a first line, highly potent chemotherapeutic. When administered systemically, it is highly toxic to healthy tissue and its final concentration is significantlly reduced since it has to cross the blood brain barrier. Also, it cannot be administered right after surgery, delaying chemotherapy by a few weeks. Double Bond’s drug delivery platform allows a high concentration of temozolomide to be released slowly and directly to the tumour right after surgery. Research to date on SI053’s use as a treatment for glioblastoma has been highly promising. Double Bond now aims to clinically validate SI053 in a clinical trial, demonstrating proof of concept.
The current proposed Phase 1 project will facilitate in the development process and help define clinical and business strategies. SME Instrument funding will allow SI053 to take a substantial step along the path of commercialisation.
Field of science
- /medical and health sciences/clinical medicine/surgery
- /medical and health sciences/clinical medicine/cancer
- /social sciences/economics and business/business and management/commerce
Call for proposal
See other projects for this call